Strikingly, EZH2 appears to function as a crosstalk regulator between cancer and T cells and modulation of EZH2 expression in cancer cells alters their ability to produce Th1-type chemokines and to attract CD8+ T effector cells, which mediate anti-tumor function especially in the context of checkpoint blockade immunotherapy. The gene discussed is CD8A; the disease is neoplasm.